Del.icio.us
Google
Yahoo MyWeb
Facebook
LigoCyte Overview
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply...More»
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry.
(Source: LigoCyte)«Less
Key People
Management
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 04/2008 | Series B | 28M | Unknown |
Products
| Name: | CD 62 Anti-Inflammatory Antibody Program |
| Product URL: | http://www.ligocyte.com/pdf/CD62.pdf |
| Description: | An anitbody used to treat patients with respiratory inflammation. Deals with chronic obstructive pulmonary disease and acute exacerbations of chronic obstructive pulmonary disease. |
Competitors
Profile
OpinionsRelated Companies
No related companies were found.
Page Information
02/24/2009 11:03AM by dylanb
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
News & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
LIGOCYTE PHARMACEUTICALS ANNOUNCES COLLABORATION WITH BIOGEN IDEC TO DEVELOP ANTI-CD103 THERAPIES
Apr 1, 2008 - 0 comments
LigoCyte on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...